By Colin Kellaher
Eyenovia on Friday said it is exploring its strategic options following the failure of a late-stage study of its proposed treatment for nearsightedness in children.
The ophthalmic technology company said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform as a potential treatment for pediatric progressive myopia after an independent review found that the trial wasn't meeting its primary three-year efficacy endpoint.
Eyenovia said it will now reduce expenses and consider a variety of options to maximize value for its shareholders, including a business combination, reverse merger or asset sales.
Trading in shares of the New York company, which closed Thursday at 34 cents, was halted premarket on Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2024 07:21 ET (12:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。